{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T11:57:55Z","timestamp":1773230275660,"version":"3.50.1"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004595","name":"Universiti Sains Malaysia","doi-asserted-by":"publisher","award":["1001\/PFARMASI\/8011119"],"award-info":[{"award-number":["1001\/PFARMASI\/8011119"]}],"id":[{"id":"10.13039\/501100004595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.vhri.2025.101089","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T04:10:42Z","timestamp":1739938242000},"page":"101089","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Cost-Effectiveness Analysis of Idursulfase for the Long-Term Treatment of Hunter Syndrome Using a Partitioned-Survival Model Approach in R"],"prefix":"10.1016","volume":"46","author":[{"given":"Khairu Hazwan","family":"Mustaffa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asrul Akmal","family":"Shafie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lock-Hock","family":"Ngu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rowani","family":"Mohd-Rawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vhri.2025.101089_bib1","first-page":"11","article-title":"Diagnosis and management of patients with mucopolysaccharidoses in Malaysia","volume":"4","author":"Ngu","year":"2018","journal-title":"J\u00a0Mucopolysaccharidosis Rare Dis"},{"issue":"1","key":"10.1016\/j.vhri.2025.101089_bib2","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1186\/s13023-021-02052-4","article-title":"Evaluation of the long-term treatment effects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling: data from the Hunter Outcome Survey (HOS)","volume":"16","author":"Muenzer","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.vhri.2025.101089_bib3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13023-020-01368-x","article-title":"Assessing the impact of the five senses on quality of life in mucopolysaccharidoses","volume":"15","author":"Giugliani","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"10.1016\/j.vhri.2025.101089_bib4","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00431-013-1967-x","article-title":"Development of a mnemonic screening tool for identifying subjects with Hunter syndrome","volume":"172","author":"Cohn","year":"2013","journal-title":"Eur J Pediatr"},{"issue":"1","key":"10.1016\/j.vhri.2025.101089_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-017-0635-z","article-title":"Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registry","volume":"12","author":"Muenzer","year":"2017","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.vhri.2025.101089_bib6","first-page":"3","article-title":"Rare diseases, orphan drugs, and their regulation in Asia: current status and future perspectives","volume":"1","author":"Song","year":"2012","journal-title":"Intractable Rare Dis Res"},{"issue":"2","key":"10.1016\/j.vhri.2025.101089_bib7","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/hsc.12070","article-title":"Projecting social support needs of informal caregivers in Malaysia","volume":"22","author":"Abu Bakar","year":"2014","journal-title":"Health Soc Care Community"},{"issue":"4","key":"10.1016\/j.vhri.2025.101089_bib8","first-page":"120","article-title":"Parental experience of enzyme replacement therapy for Hunter syndrome","volume":"106","author":"Buraczewska","year":"2013","journal-title":"Ir Med J"},{"issue":"4","key":"10.1016\/j.vhri.2025.101089_bib9","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3390\/ijms21041258","article-title":"Mucopolysaccharidosis type II: one hundred years of research, diagnosis, and treatment","volume":"21","author":"D\u2018Avanzo","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.vhri.2025.101089_bib10","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/GIM.0b013e318206786f","article-title":"Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey","volume":"13","author":"Muenzer","year":"2011","journal-title":"Genet Med"},{"issue":"7","key":"10.1016\/j.vhri.2025.101089_bib11","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/GIM.0b013e31817701e6","article-title":"Initial report from the Hunter Outcome Survey","volume":"10","author":"Wraith","year":"2008","journal-title":"Genet Med"},{"issue":"6","key":"10.1016\/j.vhri.2025.101089_bib12","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s10545-017-0075-x","article-title":"Survival in idursulfase-treated and untreated patients with mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS)","volume":"40","author":"Burton","year":"2017","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"2","key":"10.1016\/j.vhri.2025.101089_bib13","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ymgme.2019.07.016","article-title":"Ten years of enzyme replacement therapy in paediatric onset mucopolysaccharidosis II in England","volume":"129","author":"Broomfield","year":"2020","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.vhri.2025.101089_bib15","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/1750-1172-8-124","article-title":"Systematic review of available evidence on 11 high-priced inpatient orphan drugs","volume":"8","author":"Kanters","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"10.1016\/j.vhri.2025.101089_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0230850","article-title":"Rare disease in Malaysia: challenges and solutions","volume":"15","author":"Shafie","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.vhri.2025.101089_bib17","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s13023-019-1168-4","article-title":"Analysis of economic burden and its associated factors of twenty-three rare diseases in Shanghai","volume":"14","author":"Cai","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"10.1016\/j.vhri.2025.101089_bib18","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.healthpol.2014.12.016","article-title":"Socio-economic burden of rare diseases: A systematic review of cost of illness evidence","volume":"119","author":"Angelis","year":"2015","journal-title":"Health Policy"},{"issue":"suppl 1","key":"10.1016\/j.vhri.2025.101089_bib19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10198-016-0787-0","article-title":"Social\/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe","volume":"17","author":"Pentek","year":"2016","journal-title":"Eur J Health Econ"},{"issue":"3","key":"10.1016\/j.vhri.2025.101089_bib20","first-page":"1","article-title":"Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study","volume":"10","author":"Guffon","year":"2015","journal-title":"Orphanet J Rare Dis"},{"issue":"39","key":"10.1016\/j.vhri.2025.101089_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16390","article-title":"The effectiveness and cost of enzyme replacement and substrate reduction therapies: a longitudinal cohort study of people with lysosomal storage disorders","volume":"16","author":"Wyatt","year":"2012","journal-title":"Health Technol Assess"},{"issue":"1","key":"10.1016\/j.vhri.2025.101089_bib22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13023-016-0503-2","article-title":"Health-related quality of life in mucopolysaccharidosis: looking beyond biomedical issues","volume":"11","author":"Hendriksz","year":"2016","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"10.1016\/j.vhri.2025.101089_bib23","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s10897-014-9791-7","article-title":"Health-related quality of life in patients with MPS II","volume":"24","author":"Needham","year":"2015","journal-title":"J\u00a0Genet Couns"},{"issue":"1","key":"10.1016\/j.vhri.2025.101089_bib24","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s10545-014-9679-6","article-title":"The NCS-LSD cohort study: a description of the methods and analyses used to assess the long-term effectiveness of enzyme replacement therapy and substrate reduction therapy in patients with lysosomal storage disorders","volume":"37","author":"Henley","year":"2014","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"1","key":"10.1016\/j.vhri.2025.101089_bib25","doi-asserted-by":"crossref","first-page":"117","DOI":"10.36469\/jheor.2022.33801","article-title":"Clinical characteristics and healthcare resource utilization for patients with mucopolysaccharidosis II (MPS II) in the United States: a retrospective chart review","volume":"9","author":"Ayodele","year":"2022","journal-title":"J\u00a0Health Econ Outcomes Res"},{"issue":"3","key":"10.1016\/j.vhri.2025.101089_bib26","doi-asserted-by":"crossref","first-page":"190","DOI":"10.5582\/irdr.2021.01091","article-title":"The usage of enzyme replacement treatments, economic burden, and quality of life of patients with four lysosomal storage diseases in Shanghai, China","volume":"10","author":"Hu","year":"2021","journal-title":"Intractable Rare Dis Res"},{"key":"10.1016\/j.vhri.2025.101089_bib27","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.vhri.2019.01.009","article-title":"Healthcare resource utilization and the cost of care for mucopolysaccharidosis I patients in Iran","volume":"18","author":"Davari","year":"2019","journal-title":"Value Health Reg Issues"},{"issue":"8","key":"10.1016\/j.vhri.2025.101089_bib28","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.jval.2011.07.006","article-title":"Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -Intolerant chronic phase chronic myeloid leukemia","volume":"14","author":"Hoyle","year":"2011","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.vhri.2025.101089_bib29","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1177\/0272989X16686559","article-title":"An overview of R in health decision sciences","volume":"37","author":"Jalal","year":"2017","journal-title":"Med Decis Mak"},{"issue":"7","key":"10.1016\/j.vhri.2025.101089_bib30","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s40273-020-00903-9","article-title":"R\u00a0and shiny for cost-effectiveness analyses: why and when? A hypothetical case study","volume":"38","author":"Hart","year":"2020","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"10.1016\/j.vhri.2025.101089_bib31","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s40273-017-0510-8","article-title":"A\u00a0comparison of four software programs for implementing decision analytic cost-effectiveness models","volume":"35","author":"Hollman","year":"2017","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.vhri.2025.101089_bib32","series-title":"Applied Survival Analysis Using R","author":"Moore","year":"2016"},{"key":"10.1016\/j.vhri.2025.101089_bib33","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.vhri.2019.09.002","article-title":"From evidence to policy: economic evaluations of healthcare in Malaysia-A systematic review","volume":"21","author":"Rahim","year":"2020","journal-title":"Value Health Reg Issues"},{"issue":"7","key":"10.1016\/j.vhri.2025.101089_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2015.09.2639","article-title":"How to model survival in cost-effectiveness analysis? Differences between Markov and partitioned survival analysis models","volume":"18","author":"Minacori","year":"2015","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.vhri.2025.101089_bib35","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40273-013-0123-9","article-title":"Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial","volume":"32","author":"Diaby","year":"2013","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.vhri.2025.101089_bib36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"10.1016\/j.vhri.2025.101089_bib37","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jval.2022.10.012","article-title":"Cost-effectiveness of first-line Pembrolizumab monotherapy versus chemotherapy in high programmed death-ligand 1 advanced non\u2013small cell lung cancer in the Irish healthcare setting","volume":"26","author":"Chu","year":"2023","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.vhri.2025.101089_bib39","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s40273-019-00769-6","article-title":"Cost effectiveness of Nusinersen in the treatment of patients with infantile-onset and later-onset spinal muscular atrophy in Sweden","volume":"37","author":"Zuluaga-Sanchez","year":"2019","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1016\/j.vhri.2025.101089_bib40","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jval.2018.03.004","article-title":"Challenges in research and health technology assessment of rare disease technologies: report of the ISPOR rare disease Special Interest Group","volume":"21","author":"Nestler-Parr","year":"2018","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.vhri.2025.101089_bib41","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2025.101089_bib42","series-title":"Operations Research and Health Care Policy","first-page":"281","article-title":"Application of operations research to funding decisions for treatments with rare disease","author":"Coyle","year":"2013"},{"issue":"suppl 3","key":"10.1016\/j.vhri.2025.101089_bib43","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1007\/s11606-014-2885-y","article-title":"Application of a policy framework for the public funding of drugs for rare diseases","volume":"29","author":"Winquist","year":"2014","journal-title":"J\u00a0Gen Intern Med"},{"issue":"3","key":"10.1016\/j.vhri.2025.101089_bib44","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00431-007-0635-4","article-title":"Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy","volume":"167","author":"Wraith","year":"2008","journal-title":"Eur J Pediatr"},{"issue":"5","key":"10.1016\/j.vhri.2025.101089_bib45","doi-asserted-by":"crossref","first-page":"e1258","DOI":"10.1542\/peds.2010-1274","article-title":"Natural progression of neurological disease in mucopolysaccharidosis Type II","volume":"127","author":"Holt","year":"2011","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.vhri.2025.101089_bib46","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1469-8749.1983.tb13794.x","article-title":"The natural history of the severe form of Hunter\u2018s syndrome: a study based on 52 cases","volume":"25","author":"Young","year":"1983","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.vhri.2025.101089_bib47","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13023-014-0129-1","article-title":"Clinical efficacy of enzyme replacement therapy in paediatric Hunter patients, an independent study of 3.5 years","volume":"9","author":"Tomanin","year":"2014","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"10.1016\/j.vhri.2025.101089_bib48","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s10545-009-1119-7","article-title":"Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS)","volume":"32","author":"Jones","year":"2009","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"1","key":"10.1016\/j.vhri.2025.101089_bib49","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/1471-2288-11-139","article-title":"Improved curve fits to summary survival data: application to economic evaluation of health technologies","volume":"11","author":"Hoyle","year":"2011","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"10.1016\/j.vhri.2025.101089_bib50","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1177\/1536867X1801700402","article-title":"Reconstructing time-to-event data from published Kaplan-Meier curves","volume":"17","author":"Wei","year":"2017","journal-title":"Stata J"},{"issue":"1","key":"10.1016\/j.vhri.2025.101089_bib51","article-title":"A\u00a0method for reconstructing individual patient data from Kaplan-Meier survival curves that incorporate marked censoring times","volume":"7","author":"Rogula","year":"2022","journal-title":"MDM Policy Pract"},{"issue":"3","key":"10.1016\/j.vhri.2025.101089_bib52","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/jrsm.1362","article-title":"Estimating hazard ratios from published Kaplan-Meier survival curves: a methods validation study","volume":"10","author":"Saluja","year":"2019","journal-title":"Res Synth Methods"},{"issue":"2","key":"10.1016\/j.vhri.2025.101089_bib53","first-page":"79","article-title":"Reconstructing survival data from published Kaplan-Meier curves: an algorithm validation","volume":"2","author":"Saraiva","year":"2020","journal-title":"J\u00a0Stat Health Decis"},{"issue":"1","key":"10.1016\/j.vhri.2025.101089_bib54","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"11","key":"10.1016\/j.vhri.2025.101089_bib56","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1007\/s12325-014-0167-z","article-title":"No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing\u2013remitting multiple sclerosis","volume":"31","author":"Nixon","year":"2014","journal-title":"Adv Ther"},{"issue":"11","key":"10.1016\/j.vhri.2025.101089_bib57","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1002\/sim.2059","article-title":"Generating survival times to simulate Cox proportional hazards models","volume":"24","author":"Bender","year":"2005","journal-title":"Stat Med"},{"key":"10.1016\/j.vhri.2025.101089_bib58","author":"Faria"},{"key":"10.1016\/j.vhri.2025.101089_bib59","author":"Incerti"},{"issue":"1","key":"10.1016\/j.vhri.2025.101089_bib60","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40273-017-0583-4","article-title":"Oncology modeling for fun and profit! Key steps for busy analysts in health technology assessment","volume":"36","author":"Beca","year":"2018","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"10.1016\/j.vhri.2025.101089_bib61","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jval.2012.04.012","article-title":"Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--7","volume":"15","author":"Eddy","year":"2012","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.vhri.2025.101089_bib62","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2214.2006.00595.x","article-title":"Assessing services, supports and costs for young families under stress","volume":"32","author":"Sleed","year":"2006","journal-title":"Child Care Health Dev"},{"key":"10.1016\/j.vhri.2025.101089_bib63","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/978-3-319-67144-4_17","article-title":"Cost-of-illness in rare diseases","volume":"1031","author":"Linertova","year":"2017","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"10.1016\/j.vhri.2025.101089_bib64","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s40273-019-00771-y","article-title":"An educational review about using cost data for the purpose of cost-effectiveness analysis","volume":"37","author":"Franklin","year":"2019","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1016\/j.vhri.2025.101089_bib65","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.anr.2022.06.001","article-title":"A\u00a0comparison of self-evaluated survey and work sampling approach for estimating patient-care unit cost multiplier in genetic nursing activities","volume":"16","author":"Mustaffa","year":"2022","journal-title":"Asian Nurs Res"},{"key":"10.1016\/j.vhri.2025.101089_bib66","series-title":"Cost-effectiveness analysis of idursulfase for the treatment of Hunter syndrome in a tertiary referral cente for rare diseases in Malaysia: a partitioned survival model approach. Unpublished master\u2019s thesis","author":"Mustaffa","year":"2024"},{"issue":"1","key":"10.1016\/j.vhri.2025.101089_bib67","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1332\/174426410X482999","article-title":"A\u00a0web-based tool for adjusting costs to a specific target currency and price year","volume":"6","author":"Shemilt","year":"2010","journal-title":"Evid Policy"},{"issue":"1","key":"10.1016\/j.vhri.2025.101089_bib68","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1477-7525-10-102","article-title":"Development of the multi-attribute adolescent health utility measure (AHUM)","volume":"10","author":"Beusterien","year":"2012","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"10.1016\/j.vhri.2025.101089_bib69","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1750-1172-9-32","article-title":"Burden of disease in patients with Morquio A syndrome: results from an international patient-reported outcomes survey","volume":"9","author":"Hendriksz","year":"2014","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"10.1016\/j.vhri.2025.101089_bib70","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jval.2016.06.001","article-title":"Estimating health-state utility for economic models in clinical studies: an ISPOR good research practices task force report","volume":"19","author":"Wolowacz","year":"2016","journal-title":"Value Health"},{"issue":"8","key":"10.1016\/j.vhri.2025.101089_bib71","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135672","article-title":"Measuring health utilities in children and adolescents: a systematic review of the literature","volume":"10","author":"Thorrington","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.vhri.2025.101089_bib72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/PROM.S278258","article-title":"Deriving vignettes for the rare disease AADC deficiency using parent, caregiver and clinician interviews to evaluate the impact on health-related quality of life","volume":"12","author":"Hanbury","year":"2021","journal-title":"Patient Relat Outcome Meas"},{"key":"10.1016\/j.vhri.2025.101089_bib73","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2147\/CEOR.S214084","article-title":"Estimation of the quality of life benefits associated with treatment for spinal muscular atrophy","volume":"11","author":"Lloyd","year":"2019","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.vhri.2025.101089_bib74","doi-asserted-by":"crossref","first-page":"S711","DOI":"10.1016\/j.jval.2020.08.1854","article-title":"Deriving vignettes for a rare disease using parent, caregiver and clinician interviews to evaluate the impact on health-related quality of life","volume":"23","author":"Smith","year":"2020","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.vhri.2025.101089_bib75","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s41687-019-0093-6","article-title":"Health utilities and parental quality of life effects for three rare conditions tested in newborns","volume":"3","author":"Simon","year":"2019","journal-title":"J\u00a0Patient Rep Outcomes"},{"issue":"1","key":"10.1016\/j.vhri.2025.101089_bib76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.seizure.2009.10.003","article-title":"Cost-utility analysis of Rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox\u2013Gastaut syndrome in the United Kingdom","volume":"19","author":"Verdian","year":"2010","journal-title":"Seizure"},{"issue":"6","key":"10.1016\/j.vhri.2025.101089_bib77","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/sj.bjc.6603326","article-title":"Health state utilities for metastatic breast cancer","volume":"95","author":"Lloyd","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.vhri.2025.101089_bib78","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1750-1172-8-101","article-title":"The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life","volume":"8","author":"Raluy-Callado","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"10.1016\/j.vhri.2025.101089_bib79","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1007\/s11136-014-0703-y","article-title":"The Hunter Syndrome-Functional Outcomes for Clinical Understanding Scale (HS-FOCUS) Questionnaire: item reduction and further validation","volume":"23","author":"Wiklund","year":"2014","journal-title":"Qual Life Res"},{"issue":"1","key":"10.1016\/j.vhri.2025.101089_bib80","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s12955-018-1006-8","article-title":"Validation of the shortened Hunter Syndrome-Functional Outcomes for Clinical Understanding Scale (HS-FOCUS)","volume":"16","author":"Mattera","year":"2018","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.vhri.2025.101089_bib81","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/2328402","article-title":"Mucopolysaccharidosis type II: a Kenyan case series","volume":"2021","author":"Mungai","year":"2021","journal-title":"Int J Endocrinol"},{"issue":"1","key":"10.1016\/j.vhri.2025.101089_bib82","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1590\/S0124-00642012000100012","article-title":"The cost-effectiveness of enzyme replacement therapy (ERT) for the infantile form of Pompe disease: comparing a high-income country\u2018s approach (England) to that of a middle-income one (Colombia)","volume":"14","author":"Castro-Jaramillo","year":"2012","journal-title":"Rev Salud Publ (Bogota)"},{"issue":"2","key":"10.1016\/j.vhri.2025.101089_bib83","doi-asserted-by":"crossref","first-page":"147","DOI":"10.36469\/9896","article-title":"A\u00a0criterion-based approach for the systematic and transparent extrapolation of clinical trial survival data","volume":"2","author":"Tremblay","year":"2015","journal-title":"J\u00a0Health Econ Outcomes Res"},{"key":"10.1016\/j.vhri.2025.101089_bib84","series-title":"Pharmacoeconomic Guideline for Malaysia","year":"2019"},{"issue":"6","key":"10.1016\/j.vhri.2025.101089_bib85","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jval.2012.04.014","article-title":"Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6","volume":"15","author":"Briggs","year":"2012","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.vhri.2025.101089_bib86","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jval.2020.01.004","article-title":"Value of information analytical methods: report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force","volume":"23","author":"Rothery","year":"2020","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.vhri.2025.101089_bib87","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/0272989X13511302","article-title":"Response to \u201csurvival analysis and extrapolation modeling of time-to-event clinical trial data for economic evaluation: an alternative approach\u201d by Bagust and Beale","volume":"34","author":"Latimer","year":"2014","journal-title":"Med Decis Mak"},{"key":"10.1016\/j.vhri.2025.101089_bib88","series-title":"Guiding the Choice of Analytic Approach for Economic Evaluations of Oncology Treatments [PhD thesis]","author":"Rafia","year":"2021"},{"issue":"6","key":"10.1016\/j.vhri.2025.101089_bib89","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s40258-019-00496-1","article-title":"Phase I\/II clinical trial-based early economic evaluation of Acalabrutinib for relapsed chronic lymphocytic leukaemia","volume":"17","author":"Vreman","year":"2019","journal-title":"Appl Health Econ Health Policy"},{"issue":"6","key":"10.1016\/j.vhri.2025.101089_bib90","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/0272989X12472398","article-title":"Survival analysis for economic evaluations alongside clinical trials--extrapolation with patient-level data: inconsistencies, limitations, and a practical guide","volume":"33","author":"Latimer","year":"2013","journal-title":"Med Decis Mak"},{"issue":"11","key":"10.1016\/j.vhri.2025.101089_bib91","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.jval.2023.08.002","article-title":"Can independently elicited adult- and child-perspective health-state utilities explain priority setting?","volume":"26","author":"Attema","year":"2023","journal-title":"Value Health"},{"issue":"suppl 1","key":"10.1016\/j.vhri.2025.101089_bib92","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1007\/s10198-013-0507-y","article-title":"Time to tweak the TTO: results from a comparison of alternative specifications of the TTO","volume":"14","author":"Versteegh","year":"2013","journal-title":"Eur J Health Econ"},{"issue":"4","key":"10.1016\/j.vhri.2025.101089_bib93","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/MLR.0b013e3181c162a2","article-title":"Using instrument-defined health state transitions to estimate minimally important differences for four preference-based health-related quality of life instruments","volume":"48","author":"Luo","year":"2010","journal-title":"Med Care"},{"key":"10.1016\/j.vhri.2025.101089_bib94","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2147\/CEOR.S92078","article-title":"Estimating health-state utility values for patients with recurrent ovarian cancer using Functional assessment of Cancer Therapy\u2013general mapping algorithms","volume":"7","author":"Hettle","year":"2015","journal-title":"Clinicoecon Outcomes Res"},{"issue":"11","key":"10.1016\/j.vhri.2025.101089_bib95","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"Dolan","year":"1997","journal-title":"Med Care"},{"issue":"1","key":"10.1016\/j.vhri.2025.101089_bib96","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13023-018-0903-6","article-title":"A\u00a0health state utility valuation study to assess the impact of treatment mode of administration in Gaucher disease","volume":"13","author":"Hadi","year":"2018","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"10.1016\/j.vhri.2025.101089_bib97","doi-asserted-by":"crossref","DOI":"10.1177\/2473974X221092381","article-title":"Defining the health utility value of medical management of chronic rhinosinusitis: a prospective pilot study","volume":"6","author":"Scangas","year":"2022","journal-title":"OTO Open"},{"issue":"6","key":"10.1016\/j.vhri.2025.101089_bib98","doi-asserted-by":"crossref","first-page":"A375","DOI":"10.1016\/S1098-3015(10)65325-9","article-title":"Cost effectiveness modelling of enzyme replacement therapy for mucopolysaccharidosis II, an ultra-orphan disease","volume":"10","author":"Thompson","year":"2007","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.vhri.2025.101089_bib99","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12962-022-00369-w","article-title":"A\u00a0systematic review of the economic evaluations of Enzyme Replacement Therapy in Lysosomal Storage Diseases","volume":"20","author":"Katsigianni","year":"2022","journal-title":"Cost Eff Resour Alloc"},{"key":"10.1016\/j.vhri.2025.101089_bib100","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1750-1172-9-75","article-title":"Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease","volume":"9","author":"Kanters","year":"2014","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.vhri.2025.101089_bib101","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13023-017-0731-0","article-title":"Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease","volume":"12","author":"Kanters","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.vhri.2025.101089_bib102","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3389\/fpubh.2016.00214","article-title":"Multi-criteria decision analysis for assessment and appraisal of orphan drugs","volume":"4","author":"Iskrov","year":"2016","journal-title":"Front Public Health"},{"issue":"5","key":"10.1016\/j.vhri.2025.101089_bib103","first-page":"eP49","article-title":"Ngu L.-H., Mohd-Rawi, R.. Estimating patient long-term survival outcomes and characterizing uncertainty associated with enzyme replacement therapy (ERT) treatment for Hunter Syndrome","volume":"77","author":"Mustaffa","year":"2022","journal-title":"Med J Malaysia"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109925000147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109925000147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T03:06:26Z","timestamp":1742439986000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109925000147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":100,"alternative-id":["S2212109925000147"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2025.101089","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness Analysis of Idursulfase for the Long-Term Treatment of Hunter Syndrome Using a Partitioned-Survival Model Approach in R","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2025.101089","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101089"}}